drugset / Trial / NCT01987739

Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

NCT01987739

Phase 1 Completed 42 enrolled Midnight Pharma, LLC
RandomizedCrossoverTriple-blind

Summary

This was a six-way crossover study with six single-dose treatment sessions. The profile of acute effects on abuse potential measures of different almorexant doses was compared to that of placebo and two doses of zolpidem

Timeline

Start
2009-09
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolpidem Small molecule 20 mg Oral
Subject Zolpidem Small molecule 40 mg Oral
Subject almorexant Small molecule 200 mg Oral
Subject almorexant Small molecule 400 mg Oral
Subject almorexant Small molecule 1000 mg Oral

Indications

No indication recorded.